These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25112529)

  • 1. Shaping of an effective immune microenvironment to and by cancer cells.
    Becht E; Goc J; Germain C; Giraldo NA; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
    Cancer Immunol Immunother; 2014 Oct; 63(10):991-7. PubMed ID: 25112529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary lymphoid structures in cancer and beyond.
    Dieu-Nosjean MC; Goc J; Giraldo NA; Sautès-Fridman C; Fridman WH
    Trends Immunol; 2014 Nov; 35(11):571-80. PubMed ID: 25443495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune microenvironment: a major player in human cancers.
    Fridman WH; Remark R; Goc J; Giraldo NA; Becht E; Hammond SA; Damotte D; Dieu-Nosjean MC; Sautès-Fridman C
    Int Arch Allergy Immunol; 2014; 164(1):13-26. PubMed ID: 24852691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of mast cells in anticancer immunity.
    Dalton DK; Noelle RJ
    Cancer Immunol Immunother; 2012 Sep; 61(9):1511-20. PubMed ID: 22527244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
    Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
    Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.
    Sautès-Fridman C; Verneau J; Sun CM; Moreira M; Chen TW; Meylan M; Petitprez F; Fridman WH
    Semin Immunol; 2020 Apr; 48():101406. PubMed ID: 33248905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
    Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
    J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
    Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
    Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment to enhance antitumor immune responses.
    Van der Jeught K; Bialkowski L; Daszkiewicz L; Broos K; Goyvaerts C; Renmans D; Van Lint S; Heirman C; Thielemans K; Breckpot K
    Oncotarget; 2015 Jan; 6(3):1359-81. PubMed ID: 25682197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
    Albini A; Bruno A; Noonan DM; Mortara L
    Front Immunol; 2018; 9():527. PubMed ID: 29675018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
    Fridman WH; Petitprez F; Sautes-Fridman C
    Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
    [No Abstract]   [Full Text] [Related]  

  • 13. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
    Trüb M; Zippelius A
    Front Immunol; 2021; 12():674565. PubMed ID: 34054861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.
    Johansson-Percival A; He B; Li ZJ; Kjellén A; Russell K; Li J; Larma I; Ganss R
    Nat Immunol; 2017 Nov; 18(11):1207-1217. PubMed ID: 28892469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
    Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.
    Weinstein AM; Storkus WJ
    Adv Cancer Res; 2015; 128():197-233. PubMed ID: 26216634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obstacles to T cell migration in the tumor microenvironment.
    Nicolas-Boluda A; Donnadieu E
    Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte trafficking: Can we bring the fight to the tumor?
    Pachynski R; Nazha J; Kohrt H
    Discov Med; 2016 Mar; 21(115):205-12. PubMed ID: 27115171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.